文献速递胃肠动力与功能性疾病

综述:胃轻瘫治疗中选择抑制呕吐或增加胃排空药物的药理学依据分析

Review article: An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-03-14

本综述通过共识意见和文献回顾识别临床用于胃轻瘫的药物,分析其药理学靶点与呕吐、胃排空机制的关系。结论认为多种抑制呕吐的药物缺乏科学依据,NK1拮抗剂有依据但对恶心的疗效有限,需针对恶心开发新方法并客观评估恶心。

要点

  • 5-HT3、D2、H1或毒蕈碱拮抗剂及米氮平、阿米替林、去甲替林抑制呕吐的依据不足。
  • NK1拮抗剂抑制迷走传入中枢效应的依据受其对恶心效果存疑的影响。
  • 甲氧氯普胺和红霉素增加胃排空但副作用令人困惑,选择性5-HT4激动剂疗效不一。

核心结论

  • 多种抑制呕吐的药物类别缺乏科学依据。
  • NK1拮抗剂有依据,但对恶心的疗效有限使情况复杂。
  • 研究须解决选择性5-HT4激动剂疗效不一及其相对胃动素激动剂的明显优势。
  • 总体缺乏稳健活性表明需要针对恶心的新方法(如调节胃起搏点或迷走活动、使用受体激动剂或GDF15等新靶点)及客观评估恶心。

研究设计与样本

  • 通过共识意见和综述识别临床使用的药物,排除特征不明确的药物,定义其药理学并映射至影响呕吐和胃排空的机制,形成治疗依据。

主要发现

  • 5-HT3、D2、H1或毒蕈碱拮抗剂及米氮平、阿米替林、去甲替林抑制呕吐的依据不足。
  • 通过NK1拮抗抑制迷走传入中枢效应的论点因对恶心效果的疑问而复杂化。
  • 甲氧氯普胺(5-HT4激动剂、D2和5-HT3拮抗剂;也阻断部分致吐刺激并引起迟发性运动障碍)和红霉素(高效胃动素激动剂,需低剂量以减少副作用)增加胃排空的副作用导致困惑。
  • 选择性5-HT4激动剂的有限试验显示疗效不一。

关键数值与推荐

  • 5-HT3、D2、H1或毒蕈碱拮抗剂及米氮平、阿米替林、去甲替林抑制呕吐的依据不足。
  • NK1拮抗抑制迷走传入中枢效应有依据,但对恶心的疗效有限使情况复杂。
  • 甲氧氯普胺为5-HT4激动剂、D2和5-HT3拮抗剂,也阻断部分致吐刺激并引起迟发性运动障碍。
  • 红霉素为高效胃动素激动剂,需低剂量以减少副作用。
  • 选择性5-HT4激动剂试验有限,疗效不一。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drugs which can inhibit nausea/vomiting and/or increase gastric emptying are used to treat gastroparesis, mostly 'off-label'. Within each category, they act at different targets and modulate different physiological mechanisms. AIMS: Address the questions: In gastroparesis, why should blocking one pathway causing vomiting, be more appropriate than another? Why might increasing gastric emptying via one mechanism be more appropriate than another? METHODS: Drugs used clinically were identified via consensus opinions and reviews, excluding the poorly characterised. Their pharmacology was defined, mapped to mechanisms influencing vomiting and gastric emptying, and rationale developed for therapeutic use. RESULTS: Vomiting: Rationale for 5-HT3 , D2 , H1 or muscarinic antagonists, and mirtazapine, amitriptyline, nortriptyline, are poor. Arguments for inhibiting central consequences of vagal afferent transmission by NK1 antagonism are complicated by doubts over effects on nausea. Gastric emptying: Confusion emerges because of side-effects of drugs increasing gastric emptying: Metoclopramide (5-HT4 agonist, D2 and 5-HT3 antagonist; also blocks some emetic stimuli and causes tardive dyskinesia) and Erythromycin (high-efficacy motilin agonist, requiring low doses to minimise side-effects). Limited trials with selective 5-HT4 agonists indicate variable efficacy. CONCLUSIONS: Several drug classes inhibiting vomiting have no scientific rationale. NK1 antagonism has rationale but complicated by limited efficacy against nausea. Studies must resolve variable efficacy of selective 5-HT4 agonists and apparent superiority over motilin agonists. Overall, lack of robust activity indicates a need for novel approaches targeting nausea (e.g., modulating gastric pacemaker or vagal activity, use of receptor agonists or new targets such as GDF15) and objective assessments of nausea.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sanger GJ, Andrews PLR. Review article: An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis. Aliment Pharmacol Ther. 2023. PMID: 36919196. doi:10.1111/apt.17466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。